

Epidemiology of early- and late-onset serious bacterial infections in Australian neonates and infants: A retrospective multicentre study

Phoebe CM Williams,^{1,2*} Mona Mostaghim¹, Jackson Harrison¹, Monica Lahra³, Mark Greenhalgh⁴, Matthew O'Sullivan⁵, Michael Maley⁶, Ju-Lee Oei⁷, Archana Koirala^{8,1}, Himanshu Popat⁸, Kei Lui⁹, Brendan McMullan², Pamela Palasanthiran², Alison Kesson¹⁰, David Isaacs¹⁰, Adam W Bartlett²

¹The University of Sydney, School of Public Health, Faculty of Medicine, Sydney, NSW, AU

²Sydney Children's Hospitals Network Randwick, Department of Infectious Diseases, Sydney, NSW, AU

³Prince of Wales Hospital,, Department of Microbiology, Randwick, NSW, AU

⁴Royal Prince Alfred Hospital, Neonatology, Camperdown, NSW, AU

⁵NSW Health Pathology, Centre for Infectious Diseases and Microbiology Sydney, NSW, AU

⁶NSW Health Pathology, Microbiology and Infectious Diseases, Liverpool, NSW, AU

⁷Royal Hospital for Women Randwick , Neonatology, Sydney, NSW, AU

⁸Nepean Hospital, Department of Infectious Diseases, Penrith, AU

⁸The Children's Hospital at Westmead, Department of Neonatology, Westmead, NSW, AU

⁹Australian and New Zealand Neonatal Network, Royal Hospital for Women, National Perinatal Epidemiology and Statistic Unit, University of New South Wales, Newborn Care, Sydney, NSW, AU

¹⁰The Children's Hospital, Infectious Diseases and Microbiology, Westmead, NSW, AU

Word Count: 3,300

Abstract: 246

Figures: 2

Tables: 3

*Corresponding author: phoebe.williams@sydney.edu.au; Sydney Institute for Infectious Diseases, Edward Ford Building, University of Sydney Camperdown NSW 2006 Australia.

Funding:

Phoebe CM Williams is supported by an NHMRC investigator grant focussed on neonatal sepsis. NHMRC had no role in the design of the study or review of results.

We declare no conflicts of interest.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

ABSTRACT

Background: There has been little decline in neonatal mortality rates over recent decades, and this is now further challenged by the rising prevalence of antimicrobial resistance (AMR). In Australia, the incidence of neonatal sepsis is low on a global scale, yet there are increasingly frequent outbreaks of multidrug-resistant (MDR) infections in neonatal intensive care units, alongside rising rates of colonisation with MDR bacteria.

Methods: We analysed positive blood and cerebrospinal fluid (CSF) cultures collected from infants (aged 0 to ≤ 180 days) across five clinical sites in Australia between 2010 and 2019, to determine evolving antimicrobial susceptibility profiles.

Results: After excluding presumed contaminants, we analysed 743 pathogenic bacterial isolates cultured from 624 neonates and infants with early- (≤ 72 hours), late- (>72 hours to ≤ 28 days), and very late-onset (>28 days to ≤ 180 days) infections. *Escherichia coli* (37%) and *Streptococcus agalactiae* (31%) were the primary pathogens responsible for early-onset bloodstream infections, whilst coagulase-negative staphylococci, *E. coli* and *Staphylococcus aureus* were responsible for most infections in older neonates and infants. Antimicrobial susceptibility to currently-recommended empiric regimens remains high; however, gram-negative bacteria – including MDR bacteria – were responsible for an increasing proportion of very late-onset infections over the study period (22% in 2010-2014 versus 34% in 2015-2019; $p=0.07$).

Conclusions: Although empiric antimicrobial regimens remain adequate for most pathogens causing infections in neonates and infants in Australia, there is an increasing burden of invasive infections caused by gram-negative bacteria. Ongoing surveillance is necessary to ensure empiric antimicrobial guidelines remain efficacious and appropriate.

INTRODUCTION

Over the past three decades there has been global progress in reducing child mortality, yet the decline in neonatal mortality rates has been slower, with nearly half of all childhood deaths now occurring within the neonatal (0-28 day) period.¹ Serious bacterial infections (often referred to as ‘neonatal sepsis’) are a leading cause of child mortality, accounting for up to 700,000 newborn deaths each year - the majority of which occur in Southeast Asia and sub-Saharan Africa.^{2,3} However, as antimicrobial resistance (AMR) rises globally, the mortality and disability burden caused by multidrug-resistant organisms (MROs) – which are increasingly responsible for a larger proportion of neonatal infections – requires urgent attention across all healthcare settings.³

The newborn period bears the highest lifetime risk of sepsis.³ Multiple risk factors predispose neonates (and infants, particularly those born prematurely) to invasive bacterial infections – including immune system immaturity, poorly developed gastrointestinal and skin mucosal barriers, and exposure to invasive procedures when unwell.⁴ In Australia, neonatal sepsis incidence rates are low on an international scale, yet are gradually increasing;⁵ and the associated morbidity and mortality burden is significant.⁶

Advanced healthcare systems now enable the resuscitation and support of infants from 23-24 weeks’ gestation, and these extremely preterm infants subsequently require a prolonged hospital stay during which they are at high risk of developing late-onset sepsis (with incidence rates up to 15 times that observed term infants).^{7,8} Furthermore, premature infants are frequently prescribed multiple empiric antibiotic courses, reducing their microbiome diversity and increasing the risk of colonisation and infection with MROs.⁹

International observational studies have revealed the epidemiology of neonatal sepsis is rapidly evolving due to the growing global burden of AMR.¹⁰⁻¹² However, there are scarce published data delineating the epidemiology of neonatal infections in Australian infants, with most published literature focussing on early-onset sepsis (EOS; currently defined as infections occurring at ≤ 72 hours of age).^{6,8} While EOS is an important cause of neonatal morbidity and mortality, understanding the burden of late-onset sepsis (LOS, occurring at >72 h of age) is increasingly important as more premature infants survive and require prolonged hospitalisation.¹³

In Australia and New Zealand, LOS occurs in 44% of neonates born at <24 weeks gestational age who are admitted to tertiary neonatal intensive care units (NICUs), and in 17% of admitted infants born at 26-27 weeks gestational age.¹⁴ While LOS can occur secondary to perinatally-acquired (vertically-transmitted) pathogens, it is often the consequence of acquisition of MROs

via colonisation with bacteria present within the hospital setting.¹⁵ However, there is increasing evidence to suggest hospital-acquired bacteria may also be responsible for a significant burden of EOS, challenging the traditional rationale behind the empirical antibiotic regimens currently-recommended to treat EOS and LOS, which are based on historical data around causative bacteria.¹⁶

Australia's therapeutic guidelines recommend benzylpenicillin plus gentamicin as empiric antibiotics to treat EOS (or benzylpenicillin plus cefotaxime if meningitis is suspected),¹⁷ and an aminopenicillin plus gentamicin for infants with community-acquired LOS (cefotaxime where meningitis is suspected), with the addition of vancomycin if there is an epidemiological risk factor for methicillin-resistant *Staphylococcus aureus*. For infants aged >2 months with septic shock or meningitis, these guidelines recommend gentamicin, cefotaxime/ceftriaxone and vancomycin for infants presenting from the community.¹⁸ Most hospital- and state-based guidelines across Australia recommend neonates (and infants hospitalised since birth) with LOS are treated with flucloxacillin and gentamicin, +/- vancomycin.^{17,19–21}

Despite strong antimicrobial stewardship programs across Australia's healthcare settings, there are emerging challenges with both MRO neonatal colonisation and MRO outbreaks in NICUs,^{13,22–24} which are increasingly difficult to treat.^{25,26} As the burden of AMR evolves and neonates are resuscitated at earlier gestations, significant knowledge gaps remain in understanding the epidemiology of serious bacterial infections in neonates and infants – including evaluation as to whether the current empiric antibiotic recommendations remain appropriate.^{27,28} We aimed to address this evidence gap by analysing the contemporary bacterial pathogens (and their evolving antibiotic susceptibility profiles) responsible for both early- and late-onset serious bacterial infections in neonates and infants in New South Wales (NSW), Australia's most populous state.

METHODS:

We conducted a multicentre retrospective observational study across five clinical settings in NSW, Australia (including one rural hospital, and four tertiary urban hospitals). Laboratory databases were interrogated to systematically evaluate positive blood and cerebrospinal fluid (CSF) cultures collected between 2010-2019 (inclusive) in infants aged ≤ 180 postnatal days of age. We stratified our analysis of culture-positive infections to (i) the early neonatal period (≤ 72 hours), (ii) the late neonatal period (>72 hours to ≤ 28 days), and (iii) very late onset infections (>28 days to ≤ 180 days). State-wide data were used to ascertain denominator data for the number of livebirths within each of the study hospitals.²⁰

Cultures collected within 14 days of an index culture isolating the same pathogen were considered duplicates and removed, alongside a pre-defined list of likely contaminant bacteria (Supplementary Figure 1). Coagulase-negative staphylococci (CoNS) isolates were only retained as bloodstream infection pathogens in infants aged >72 hours of age who were admitted to the neonatal intensive care, or in CSF isolates where review of clinical data confirmed the occurrence of meningitis. CoNS isolates from neonates admitted from the community or in postnatal wards were removed as presumed contaminants.

Antimicrobial susceptibility data were attained following testing performed using automated methods (Vitek2®, BioMérieux or BD Phoenix™, Becton Dickinson, USA) and categorised by CLSI,²⁹ EUCAST,³⁰ or CDS methodology;³¹ then extracted from laboratory systems and evaluated against a pre-defined list of antibiotics (Supplementary Table 1). Pathogens with (non-inherent) non-susceptibility to three or more classes of antibiotics were classified as multidrug-resistant. Changes in causative bacteria and antimicrobial susceptibility were assessed by comparing the periods between January 2010-December 2014 and January 2015-December 2019.

Data cleaning and statistical analysis were performed in the R programming environment (R Core Team, 2023). Continuous data were reported as median and interquartile ranges, while categorical variables were reported as numbers and percentages, and compared using Chi-squared or Fisher exact tests. Poisson regression was used to assess trends in incidence over time. Ethical approval was obtained via the Sydney Children's Hospital Network Human Research Ethics Committee (2020/ETH01847).

Results:

We analysed 743 pathogenic bacterial isolates collected from 624 infants across five hospitals during the study period (Figure 1; Table 1; Supplementary Figure 1). This included 464 isolates from neonates and infants admitted to Nepean and Westmead Hospital in urban NSW, and Wagga Wagga Base Hospital in rural NSW, between 2010-2019 (inclusive); and 279 isolates from neonates and infants admitted to The Royal Hospital for Women and Sydney Children's Hospital in Eastern Sydney from 2015-2019 (a shorter period than the pre-defined study period, due to laboratory information system changes for the pathology service associated with these hospitals).

Bloodstream infections were responsible for most infection episodes (95%, 669/743), with 35 CSF infections also identified (of 743, 5%). There were 34 polymicrobial bloodstream infections (\geq two pathogenic bacteria isolated), and one CSF specimen yielded three pathogenic bacteria (Table 1). Most isolates were obtained from neonates or infants admitted to NICUs (73%, 543/743). The incidence of EOS across the study period varied from 0.6 per 1,000 livebirths to 1 per 1,000 livebirths (Supplementary Table 2), with no significant trend in EOS incidence rates observed across the study period (0.05% change in incidence per year, 95%CI -7.1% to 8.9%).

Early onset neonatal infections (\leq 72 hours of age):

Fifteen percent (106/705) of infections occurred in the EOS period (\leq 72 hours of age), with a median age of infection onset in this cohort of 0 days (IQR 0-1 day). Bloodstream infections were caused by approximately equal proportions of gram-negative (48%) and gram-positive (51%) bacteria, and there was one episode of fungaemia (due to *Candida albicans*) (Table 2; Figure 1).

Escherichia coli (37%), *Streptococcus agalactiae* (31%) and *Enterococcus faecalis* (13%) were identified as the bacteria most frequently responsible for EOS (Figure 1). The proportion of gram-negative bacteria responsible for EOS was similar across the study period (58% over 2010-2014 versus 43% over 2015-2019, $p=0.13$). Neonates who required admission to the NICU for higher-level care were more likely to have *S. agalactiae* infections (41%, versus 12% of infants admitted to postnatal wards), while neonates with *E. faecalis* infections were more likely to be admitted to the postnatal ward (32% versus 4% of infants admitted to the NICU). All CSF infections ($n=5$) in this age group were caused by gram-positive bacteria (*S. agalactiae* and *S. aureus*) (Table 2).

Late onset neonatal infections (day 3 to $<$ 28 days):

Most of the culture-positive infections identified in our study (52%, 365/705) occurred in the late-onset neonatal period (day 3 to $<$ 28 days), at a median age of 12 days (IQR 8 to 18). Within this cohort, there were 353 episodes of bacteraemia (incorporating 370 isolates, including 17 polymicrobial infections) and 12 CSF infections.

Gram-positive bacteria predominated as causative of bloodstream infections (n=278, 75%), largely due to a significant burden of CoNS isolated from neonates admitted to the NICU (209/370, 56%), followed by *S. aureus* (8%), *E. faecalis* (6%) and *S. agalactiae* (4%) infections. One episode of fungaemia was reported (due to *C. albicans*). The most frequently isolated gram-negative bacteria causative of late-onset neonatal bloodstream infections was *E. coli* (10%, 39/370), followed by *Klebsiella* spp. (5%, 17/370) and *Enterobacter cloacae* complex (14/370, 4%). The proportion of bloodstream infections caused by gram-negative bacteria was largely consistent across the two periods (21% in 2010-2014 and 27% in 2015-2019, p = 0.26). The 12 CSF infections were caused by *E. coli*, *S. agalactiae*, *S. aureus*, *Pseudomonas aeruginosa*, *Enterobacter* spp. and CoNS (Table 2).

Very late onset infections in infants (day 28-180 inclusive):

One-third of isolates included in our analysis (234/705, 33%) were cultured from infants aged 28-180 days (median age of infection at 45 days, IQR 35 to 71). Gram-positive bacteria predominated as causative of bloodstream infections in this age group (162/230, 70%), again due to a significant burden of CoNS bloodstream infections in neonates admitted to the NICU (38%, 88/230), alongside very late-onset *S. agalactiae* infections (12%, 28/230), and bloodstream infections caused by *S. aureus* (10% 22/230) and *E. faecalis* (8%, 19/230).

Among gram-negative bacteria, *E. coli* was responsible for 15% of all bloodstream infections (35/230) in this cohort, followed by *Klebsiella* spp. (10/230, 4%) and *Enterobacter* spp. (8/230, 3%). Across all hospitals, an increasing proportion of late-onset bloodstream infections were caused by gram-negative bacteria over the study period (22% over 2010-2014 versus 34% over 2015-2019; p=0.07). Among the pathogens causative of the 21 CSF infections in this cohort, *S. agalactiae* (5/21) predominated, followed by *E. coli* (4/21, 19%) and *S. aureus* (3/21).

Antimicrobial Susceptibility Profiles:

i. Gram-positive bloodstream infections:

S. agalactiae was a prominent cause of bloodstream infections across the study population (n=76 isolates), with all tested isolates susceptible to penicillins (n=76) and third-generation cephalosporins (cefotaxime/ceftriaxone, n=11/11 tested; Supplementary Table 4). Most *S. agalactiae* isolates were also susceptible to clindamycin (27/39, 70%) and erythromycin (32/44, 73%). Most *S. aureus* isolates were methicillin-susceptible (44/53, 83%), and over 90% were susceptible to clindamycin (42/46) or trimethoprim-sulfamethoxazole (25/27); whilst all

tested *S. aureus* isolates were susceptible to vancomycin (40/40). There were no statistically significant susceptibility changes among *S. aureus* isolates across the study period (Supplementary Table 3). Of 56 *E. faecalis* isolates with susceptibility data available, all tested against ampicillin (39/39) and vancomycin (55/55) were susceptible.

i. Gram-negative bloodstream infections (BSIs):

E. coli was the primary cause of gram-negative bloodstream infections in our study population (n=113; Figure 2). Of those tested, 92% demonstrated susceptibility to third-generation cephalosporins (ceftriaxone/cefotaxime; 100/109), 89% were susceptible to gentamicin/tobramycin (101/113), and 45% were susceptible to aminopenicillins (ampicillin/amoxicillin, 33/74). All *E. coli* BSI isolates tested were susceptible to amikacin (75/75) and meropenem (78/78). Trimethoprim-sulfamethoxazole susceptibility decreased for *E. coli* isolates over the study period (from 85% [33/39] in 2010-2014 to 65% [22/34] in 2015-2019, p=0.05), yet no other statistically significant changes in AST results were observed.

There were 14 episodes of MDR *E. coli* bacteraemia (defined as acquired non-susceptibility to at least one antibiotic across three or more antimicrobial classes), including eight (57%) which were extended-spectrum beta-lactamase producing pathogens). Most of these infections (9/14) occurred at the two hospitals in Western Sydney as sporadic infections (not associated with outbreaks) in the latter part of the study period (2015-2019, versus 5/14 in 2010-2014, p=0.18)

Enterobacter cloacae complex was the second most common gram-negative bacteria responsible for bloodstream infections (n=23). Most tested isolates were susceptible to meropenem (95%, 19/20), cefepime (14/16, 88%), gentamicin/tobramycin (87%), amikacin (16/16, 100%), ciprofloxacin (19/19) and trimethoprim-sulfamethoxazole (17/17). There were two MDR *E. cloacae* bloodstream infections (including one carbapenem-resistant infection), which occurred in 2017 and 2019 in infants admitted to the hospitals in Central Sydney. All tested *Klebsiella* spp. and *Pseudomonas aeruginosa* isolates had high rates of susceptibility to all antibiotics assessed (Supplementary Table 4).

iii. Antimicrobial susceptibility in CSF infections:

Gram-negative CSF infections were primarily caused by *E. coli* (7/16, 44%), with all tested CSF isolates (n=7) universally susceptible to third-generation cephalosporins (ceftriaxone/cefotaxime) and aminoglycosides (Supplementary Table 5). *Enterobacter cloacae*

complex CSF isolates (n=2) and *Pseudomonas aeruginosa* CSF isolates (n=2) were susceptible to aminoglycosides (gentamicin/tobramycin) and later-generation cephalosporins. Gram-positive CSF infections were primarily caused by *S. agalactiae*, with all isolates susceptible to penicillin (11/11) and ceftriaxone (5/5), as anticipated. One *S. aureus* CSF isolate was methicillin-resistant (of 5, 20%; Supplementary Table 6).

iv. Antimicrobial susceptibility to commonly-prescribed antibiotics:

Table 3 summarises the susceptibility of the most frequently isolated pathogens to commonly-prescribed empiric antimicrobials. *E coli* isolates from infants with very late-onset infections were less likely to be susceptible to ampicillin than those attained from neonates, though gentamicin and third-generation susceptibility remained high across all age cohorts. Methicillin-resistant *S. aureus* evolved with increasing postnatal age, with no tested isolates exhibiting methicillin-resistance in the EOS period, while 34% (day 3-27) and 13% (day 28-180) of isolates revealed methicillin-resistance in older neonates and infants (respectively). *E. faecalis* isolates were all susceptible to vancomycin for the 0-2 day cohort, yet declined to 83% in older neonates (3-27 days) and 89% in infants (28-180 days)

DISCUSSION:

Our multicentre study evaluated the pathogens responsible for serious bacterial infections in neonates and infants (up to 6 months' postnatal age) across five hospitals in urban and rural NSW, Australia. Our study revealed a significant burden of serious bacterial infections occur beyond the neonatal period, and that many of these infections are due to gram-negative bacteria, with a rising prevalence of multidrug-resistance evident over time. As healthcare settings are increasingly able to resuscitate and support extremely premature infants, prolonged hospital stay beyond the neonatal period necessitates the close monitoring of the epidemiology of these infections, particularly as the burden of AMR rises globally.

Our analysis is unique by way of inclusion of serious infections occurring beyond the neonatal period. Most published data in this field focuses on the epidemiology of early-onset neonatal infections, yet our study has revealed a substantial burden of serious bacterial infections occurring in infants. Many of these infants are prematurely-born and vulnerable to hospital-acquired infections, emphasising the need for ongoing surveillance and evaluation of the appropriateness of empiric antibiotic regimens, to ensure they remain targeted to the most likely causative pathogens. This is crucial in the context of the known challenges in confirming

microbiological diagnoses in neonates and infants with invasive infections, which often limits the capacity for directed therapy.³²

Our data reveal adequate levels of susceptibility to currently-recommended and commonly-prescribed empiric antimicrobial combinations, suggesting local empiric antibiotic guidelines for sepsis and meningitis remain appropriate, in alignment with other observational studies conducted in high-income settings.^{33,34} However, MDR gram-negative infections were more prevalent in the latter part of our study period, and invasive bacterial infections occurring beyond the EOS period were more likely to exhibit antibiotic resistance. Furthermore, more than 10% of *E. coli* isolates in our study were non-susceptible to gentamicin, which has prompted some NICUs in Australia to alter their empirical aminoglycoside to amikacin over recent years.

Our study revealed interesting findings regarding the bacteria responsible for serious bacterial infections in neonates and infants admitted to various ward settings, with those admitted to higher-dependency settings (ie, NICUs) more likely to have infections with gram-negative pathogens (*E coli*), while infants admitted to paediatric or postnatal wards at the time of their culture collection were more likely to have gram-positive infections (*Enterococcus* spp.). Whether this reflects differences in clinical acuity associated with pathogenic bacterial virulence is uncertain, and exemplifies the need for detailed prospective observational studies that incorporate both microbiological *and* clinical data.

Late-onset bloodstream infections accounted for over half of all infections in our cohort, with a substantial proportion caused by CoNS in older neonates and infants admitted to NICUs. This finding aligns with existing literature, highlighting the significant role of CoNS in NICU-acquired infections, particularly in premature infants requiring long lines and prolonged hospitalisation.³⁵ However, there was also a notable burden of gram-negative bacteria causative of late-onset infections in our cohort, highlighting the ongoing need for vigilant infection prevention and control (IPC) measures in NICU settings, to mitigate nosocomial transmission of these bacteria given their high propensity to acquire resistance mechanisms.³⁵ Although MDR infections were relatively infrequent in our cohort, their presence emphasises the critical importance of ongoing IPC and antimicrobial stewardship efforts in NICU settings. On a promising note, our study revealed a very low burden of invasive fungal infections in neonates

and infants, affirming the importance (and success) of fungal prophylaxis programs across NICU settings in Australia.³⁶

One of the main limitations of our study is the lack of clinical outcome data, which is a common challenge noted in AMR surveillance literature, and highlights the need for future prospective surveillance studies that capture both microbiological and clinical data. Another limitation in our project is the change in laboratory information systems that occurred across two hospital sites during our study period, limiting the availability of data to a shorter timeframe for those these sites. Challenges in integrating laboratory information systems to easily procure data to examine epidemiological trends in infections is a known issue in the published literature; and strategies to address this have been developed – including for resource-constrained healthcare settings, where the burden of neonatal infection is greatest.³⁷

Despite these limitations, to our knowledge this study is the most comprehensive analysis of the pathogens responsible for neonatal and infant bloodstream and CSF infections in Australia. We have revealed a low yet notable burden of serious bacterial infections caused by antibiotic-resistant bacteria, which will require close monitoring - particularly in the context of the very high rates of MDR gram-negative bacteria causing a significant neonatal sepsis burden in Australia's neighbouring Southeast Asia region.^{10–12,38,39} Furthermore, our analysis of the pathogens causing serious bacterial infections by day of life underscores the importance of continued surveillance of pathogens presumed to be responsible for EOS, both in Australia and globally.⁴⁰

Our study revealed a stable incidence of EOS, with *E coli* and *S agalactiae* identified as the predominant causative agents of EOS. While this is consistent with international data from other high-income healthcare settings, it lies in stark contrast to the bacteria causative of EOS in resource-strained healthcare settings, where MDR gram-negative infections predominate.^{10–12} Ongoing surveillance of the epidemiology of neonatal infections is clearly necessary as more babies are born and survive prematurely, and this data should incorporate wards across all geographic regions. Close monitoring of evolving susceptibility profiles in invasive infections as the burden of AMR increases is vital to improving neonatal health outcomes, and should include both microbiological and clinical data, to evaluate the impact of MDR infections on clinical outcomes.

Alongside improved clinical and microbiological surveillance, further research that identifies and evaluates effective and targeted IPC interventions to reduce late-onset infections in neonates is also necessary, to reduce the burden of nosocomial infections. Furthermore, evaluation of the transmission dynamics of MDR pathogens within NICUs, and how colonisation and invasive infection may interact, is needed to ensure any IPC interventions can be targeted and effective. Finally, interventional studies to identify novel strategies to reduce the morbidity and mortality of neonatal infections (such as the role of steroids in neonatal meningitis, or the use of probiotics to protect the infant microbiome) are necessary, concurrent to an enhanced focus on ensuring neonates can access novel antibiotics needed to effectively treat MDR infections. Together, these strategies may reduce the currently unacceptable mortality burden caused by neonatal sepsis globally.⁴¹

REFERENCES:

- 1 Hug L, Alexander M, You D, Alkema L. National, regional, and global levels and trends in neonatal mortality between 1990 and 2017, with scenario-based projections to 2030: a systematic analysis. *Lancet Glob Health* 2019; **7**: e710–20.
- 2 The World Health Organization. Newborn mortality. <https://www.who.int/news-room/fact-sheets/detail/newborn-mortality>. 2024.
- 3 Bielicki JA. Neonatal sepsis: a complex high-impact global health challenge urgently requiring prioritization. *Clinical Microbiology and Infection* 2024; **30**: 20–1.
- 4 Dramowski A, Aucamp M, Beales E, *et al*. Healthcare-Associated Infection Prevention Interventions for Neonates in Resource-Limited Settings. *Front Pediatr* 2022; **10**.
- 5 Australian Commission on Safety and Quality in Healthcare. Epidemiology of Sepsis in Australian Public Hospitals: A Mixed Methods, National Longitudinal Study (2013-2018) . Macquarie University , 2020.
- 6 Singh T, Barnes EH, Isaacs D. Early-onset neonatal infections in Australia and New Zealand, 2002–2012. *Arch Dis Child Fetal Neonatal Ed* 2019; **104**: F248 LP-F252.
- 7 Mendoza-Palomar N, Balasch-Carulla M, González-Di Lauro S, *et al*. Escherichia coli early-onset sepsis: trends over two decades. *Eur J Pediatr* 2017; **176**: 1227–34.
- 8 Braye K, Foureur M, de Waal K, Jones M, Putt E, Ferguson J. Epidemiology of neonatal early-onset sepsis in a geographically diverse Australian health district 2006-2016. *PLoS One* 2019; **14**: e0214298.
- 9 Murray CJL, Ikuta KS, Sharara F, *et al*. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *The Lancet* 2022; **399**: 629–55.
- 10 Sands K, Carvalho MJ, Portal E, *et al*. Characterization of antimicrobial-resistant Gram-negative bacteria that cause neonatal sepsis in seven low- and middle-income countries. *Nat Microbiol* 2021; **6**: 512–23.
- 11 Dickson BFR, Putri ND, Adrizain R, *et al*. High burden of anti-microbial resistance among neonatal blood stream infections in Southeast Asia: results of the NeoSEAP study. *medRxiv* 2023; : 2023.09.11.23295383.
- 12 Russell NJ, Stöhr W, Plakkal N, *et al*. Patterns of antibiotic use, pathogens, and prediction of mortality in hospitalized neonates and young infants with sepsis: A global neonatal sepsis observational cohort study (NeoOBS). *PLoS Med* 2023; **20**: e1004179.
- 13 Howard-Jones AR, Janto C, Jennings Z, *et al*. Prompt control of a *Serratia marcescens* outbreak in a neonatal intensive care unit informed by whole-genome sequencing and comprehensive infection control intervention package. *Antimicrobial stewardship & healthcare epidemiology : ASHE* 2022; **2**: e104.
- 14 Australia and New Zealand Neonatal network (ANZNN). Report of the Australian and New Zealand Neonatal Network. 2019.
- 15 Darlow BA, Voss L, Lennon DR, Grimwood K. Early-onset neonatal group B streptococcus sepsis following national risk-based prevention guidelines. *Aust N Z J Obstet Gynaecol* 2016; **56**: 69–74.
- 16 Harrison ML, Dickson BFR, Sharland M, Williams PCM. Beyond Early- and Late-onset Neonatal Sepsis Definitions: What are the Current Causes of Neonatal Sepsis Globally? A Systematic Review and Meta-analysis of the Evidence. *Pediatr Infect Dis J* 2024; published online Sept. DOI:10.1097/INF.0000000000004485.
- 17 Therapeutic Guidelines. Empirical Antibiotic Regimens for sepsis or septic shock. Melbourne: Therapeutic Guidelines Limited; 2015 Jul. .
- 18 Therapeutic Guidelines. Empirical Antibiotic Regimens for sepsis or septic shock. Melbourne: Therapeutic Guidelines Limited; 2015 Jul. .

- 19 Government of Western Australia Child & Adolescent Health Service. Sepsis: Neonatal. Perth, 2024.
- 20 SA Maternal N& GC of P. Clinical Guideline Early Onset Neonatal Sepsis. South Australian Perinatal Practice Guidelines Early Onset Neonatal Sepsis. 2017.
- 21 Canberra Health Services. Neonatal bacterial sepsis. 2021.
https://www.canberrahealthservices.act.gov.au/__data/assets/word_doc/0011/1981496/Neonatal-Bacterial-Sepsis-.docx (accessed Nov 1, 2024).
- 22 Ponnampalavanar S, Ahmad Kamar A, Zhazali R, Kaur Basauhra Singh H, Mohd Musa M, Kamarulzaman A. An outbreak of multidrug resistant organisms in a neonatal intensive care unit in Malaysia. *Infect Dis Health* 2017; **22**: S3.
- 23 Munnoch S, Deane J, Varadhan H, *et al.* An outbreak of Carbapenemase-producing Enterobacteriaceae in a neonatal intensive care unit, NSW, Australia. *Infect Dis Health* 2018; **23**: S15.
- 24 Williams PCM, Bartlett AW, Palasanthiran P, Armstrong B, McMullan B. Successful Treatment of Invasive Carbapenemase-Producing Enterobacteriaceae Infections in Children Using Carbapenem-Aminoglycoside Combination Therapy: A Case Series. *in submission* 2019.
- 25 Williams PC, Qazi SA, Agarwal R, *et al.* Antibiotics needed to treat multidrug-resistant infections in neonates. *Bull World Health Organ* 2022; **100**: 797–807.
- 26 Koirala A, Krishnappa B, Banh C, Brandenburg U, Findlay M, Williams PCM. Successful Use of Cefiderocol to Treat a Multidrug-resistant *Stenotrophomonas maltophilia* Ventilator-associated Pneumonia in an Extremely Preterm Neonate. *Pediatr Infect Dis J* 2023; published online July.
DOI:10.1097/INF.0000000000004051.
- 27 Seale AC, Head MG, Fitchett EJA, *et al.* Neonatal infection: a major burden with minimal funding. *Lancet Glob Health* 2015; **3**: e669–70.
- 28 Limmathurotsakul D, Dunachie S, Fukuda K, *et al.* Improving the estimation of the global burden of antimicrobial resistant infections. *Lancet Infect Dis* 2019; **19**: e392–8.
- 29 CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 27th edition, CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2017. 2017.
- 30 European Committee on Antimicrobial Susceptibility (EUCAST). Clinical breakpoints and guidance. 2024.
- 31 Bell S, Pham J, Rafferty D, Allerton J. Antibiotic susceptibility testing by the CDS method (9th edition). 2018. <http://cdstest.net/> (accessed June 14, 2019).
- 32 Klingenberg C, Kornelisse RF, Buonocore G, Maier RF, Stocker M. Culture-Negative Early-Onset Neonatal Sepsis - At the Crossroad Between Efficient Sepsis Care and Antimicrobial Stewardship. *Front Pediatr* 2018; **6**: 285.
- 33 Cailes B, Kortsalioudaki C, Buttery J, *et al.* Antimicrobial resistance in UK neonatal units: neonIN infection surveillance network. *Arch Dis Child Fetal Neonatal Ed* 2018; **103**: F474–8.
- 34 Cailes B, Kortsalioudaki C, Buttery J, *et al.* Epidemiology of UK neonatal infections: the neonIN infection surveillance network. *Arch Dis Child Fetal Neonatal Ed* 2018; **103**: F547–53.
- 35 Yusef D, Shalakhti T, Awad S, Algharaibeh H, Khasawneh W. Clinical characteristics and epidemiology of sepsis in the neonatal intensive care unit in the era of multi-drug resistant organisms: A retrospective review. *Pediatr Neonatol* 2018; **59**: 35–41.
- 36 Blyth CC, Chen SCA, Slavin MA, *et al.* Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. *Pediatrics* 2009; **123**: 1360–8.

- 37 Turner P, Rupali P, Opintan JA, *et al.* Laboratory informatics capacity for effective antimicrobial resistance surveillance in resource-limited settings. *Lancet Infect Dis* 2021; **21**: e170–4.
- 38 Williams PCM, Jones M, Snelling TL, *et al.* Coverage gaps in empiric antibiotic regimens used to treat serious bacterial infections in neonates and children in Southeast Asia and the Pacific. *The Lancet Regional Health - Southeast Asia* 2024; **22**. DOI:10.1016/j.lansea.2023.100291.
- 39 Dwi Putri N, Dickson BF, Baker J, *et al.* Epidemiology of Neonatal Sepsis in Indonesia: High Burden of Multidrug-Resistant Infections Reveals Poor Coverage Provided by Currently-Recommended Neonatal Sepsis Treatment Regimens. *SSRN: Preprints with the Lancet* 2023. DOI:10.2139/ssrn.4519552.
- 40 Harrison ML, Dickson BFR, Sharland M, Williams PCM. Beyond Early- and Late-onset Neonatal Sepsis Definitions: What are the Current Causes of Neonatal Sepsis Globally? A Systematic Review and Meta-analysis of the Evidence. *Pediatr Infect Dis J* 2024; published online Sept. DOI:10.1097/INF.0000000000004485.
- 41 Williams PC, Qazi SA, Agarwal R, *et al.* Antibiotics needed to treat multidrug-resistant infections in neonates. *Bull World Health Organ* 2022; **100**: 797–807.

Tables & Figures

Table 1: Demographic characteristics

	Total	Day 0-2	Day 3-27	Day 28-180
	n (%) or median (IQR)			
Number of infection episodes	705	106	365	234
Patients	624	103	342	211
Gender				
Female	291 (41)	41 (39)	152 (42)	98 (42)
Male	406 (58)	57 (54)	213 (58)	136 (58)
Unknown	8 (1)	8 (7.5)	0	0
Age	16 (7-35)	0 (0-1)	12 (8-18)	45 (35-70.5)
NICU	543 (77)	75 (71)	321 (88)	147 (63)
Year				
2010-2014	252 (36)	38 (36)	140 (38)	74 (32)
2015 - 2019	453 (64)	68 (64)	225 (62)	160 (68)
Specimen type				
Bloodstream	669 (95)	101 (95)	353 (97)	215 (92)
Cerebrospinal Fluid	36 (5)	5 (5)	12 (3)	19 (8)
Polymicrobial Infections[^]				
Bloodstream	34 (5)	4 (4)	17(5)	13 (6)
Cerebrospinal Fluid	1 (<1)	0	0	1 (5)
Hospital				
Nepean Hospital	137 (19)	30 (28)	70 (19)	37 (16)
Royal Hospital for Women	165 (23)	17 (16)	96 (26)	52 (22)
Sydney Children's Hospital	98 (14)	8 (8)	27 (7)	63 (27)
Wagga Wagga Base Hospital	18 (3)	8 (8)	7 (2)	8 (3)
The Children's Hospital at Westmead	287 (41)	48 (45)	165 (45)	74 (32)

[^] % of specimen type

Table 2: Bacteria causative of bloodstream and CSF infections in neonates and infants 0-180 days of age

Data are n (%); ^Coagulase negative staphylococcus excluded when reported on general wards or day 0-2 of life

	Blood			Cerebrospinal fluid			Total
	Day 0-2 n=105	Day 3-27 n= 370	Day 28-180 n= 230	Day 0-2 n= 5	Day 3-27 n= 12	Day 28-180 n= 21	
Gram-negative bacteria	50 (48)	91(25)	68 (30)	0 (n/a)	5 (42)	11 (52)	225
<i>Escherichia coli</i>	39 (37)	39 (10)	35 (15)	0	3 (25)	4 (19)	120
<i>Klebsiella</i> spp.	3 (3)	17 (5)	10 (4)	0	0	1 (5)	31
<i>Pseudomonas</i> spp.	2 (2)	10 (3)	4 (2)	0	1 (8)	2 (9.5)	19
<i>Enterobacter</i> spp.	1 (1)	14 (4)	8 (3)	0	1 (8)	1 (5)	25
<i>Serratia marcescens</i>	1 (1)	3 (1)	4 (2)	0	0	1 (5)	9
<i>Acinetobacter</i> spp.	1 (1)	6 (2)	4 (2)	0	0	0	11
Other gram-negative bacteria	3 (3)	2 (0.5)	3 (1)	0	0	2 (10)	10
Gram-positive bacteria	54 (51)	278 (75)	162 (70)	5 (100)	7 (58)	10(48)	516
Coagulase negative staphylococcus^	n/a	209 (56)	88 (38)	0	3 (25)	2 (10)	302
<i>Enterococcus faecalis</i>	14(13)	23 (6)	19 (8)	0	1 (8)	n/a	57
<i>Streptococcus agalactiae</i>	33(31)	15 (4)	28 (12)	4(80)	2 (17)	5 (24)	87
<i>Staphylococcus aureus</i>	3 (3)	28 (8)	22 (10)	1(20)	1 (8)	3 (14)	58
Other gram-positive bacteria	4 (4)	3 (1)	5 (2)	0	0	0	12
Fungal	1 (1)	1 (<1)	0	0	0	0	2
<i>Candida albicans</i>	1(1)	1 (<1)	0	0	0	0	2

Table 3: Susceptibility profiles of the five most common pathogens causative of invasive (bloodstream and CSF) infections

Summarised according to commonly-recommended antimicrobial combinations, by age cohort.

N/A: Not applicable, including due to intrinsic resistance mechanisms

	Total number of isolates	Ampicillin (isolates tested, % susceptible)	Gentamicin (isolates tested, % susceptible)	Flucloxacillin (isolates tested, % susceptible)	Vancomycin (isolates tested, % susceptible)	Ceftriaxone/ Cefotaxime (isolates tested, % susceptible)
<i>Escherichia coli</i>	39	32 (41%)	39 (82%)	N/A	2 (100%)	38 (89%)
<i>Streptococcus agalactiae</i>	37	N/A	NA	N/A	N/A	3 (100%)
<i>Enterococcus faecalis</i>	14	11 (91%)	2 (100)	N/A	13 (100%)	N/A
<i>Staphylococcus aureus</i>	4	N/A	N/A	4 (100)	4 (100%)	N/A
<i>Klebsiella</i> spp.	3	1 (0%)	3 (67%)	N/A	N/A	3 (67%)

0-2 days (inclusive)


	Total number of isolates	Ampicillin (isolates tested, % susceptible)	Gentamicin (isolates tested, % susceptible)	Flucloxacillin (isolates tested, % susceptible)	Vancomycin (isolates tested, % susceptible)	Ceftriaxone/ Cefotaxime (isolates tested, % susceptible)
<i>Coagulase negative staphylococcus</i>	212	1 (100%)	1 (100%)	192 (8%)	185 (96%)	1 (100%)
<i>Escherichia coli</i>	42	28 (50%)	41 (90%)	1 (100%)	1 (100%)	39 (87%)
<i>Staphylococcus aureus</i>	29	1 (100%)	N/A	29 (66%)	23 (83%)	N/A
<i>Enterococcus faecalis</i>	24	16 (94%)	3 (100%)	4 (25%)	24 (83%)	N/A
<i>Klebsiella</i> spp.	17	N/A	3 (100%)	N/A	1 (100%)	5 (100%)

Day 3 to 27 (inclusive)


	Total number of isolates	Ampicillin (isolates tested, % susceptible)	Gentamicin (isolates tested, % susceptible)	Flucloxacillin (isolates tested, % susceptible)	Vancomycin (isolates tested, % susceptible)	Ceftriaxone/ Cefotaxime (isolates tested, % susceptible)
<i>Coagulase negative staphylococcus</i>	90	84 (0%)	84 (0%)	82 (6%)	78 (95%)	84 (0%)
<i>Escherichia coli</i>	39	27 (4%)	38 (8%)	39 (0%)	1 (100%)	38 (92%)
<i>Streptococcus agalactiae</i>	33	33 (0%)	33 (0%)	33 (0%)	1 (100%)	33 (30%)
<i>Staphylococcus aureus</i>	25	25 (0%)	25 (0%)	23 (87%)	15 (87%)	25 (0%)
<i>Enterococcus faecalis</i>	19	19 (5%)	18 (0%)	19 (0%)	19 (90%)	N/A


Day 28-180 (inclusive)

Figure 1
Incidence of common pathogens causing infections in neonates and infants by day of postnatal age; across day 0 to 7 (a); and day 0 to 180d (b)




(a) Pathogens responsible for invasive infections in neonates over the first week of life.
 *Organisms included in 'other' gram-negative: *Acinetobacter* spp., *Burkholderia cepacia*, *Citrobacter freundii*, *Enterobacter* spp., *Klebsiella* spp., *Morganella morganii*, *Serratia marcescens*, *Pseudomonas* spp. and 'other' gram-positive: *Streptococcus anginosus*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*






(b) Incidence of common pathogens causative of invasive infections in neonates and young infants across day 0-180.
NB: Note the variation in the y axis based on pathogen prevalence. Two CoNS infections reported in infants admitted to postnatal wards were from clinically-confirmed CNS infections

Figure 2
Bacterial pathogens causative of (a) bloodstream (b) CSF infections in neonates and infants



(a) Bloodstream infections




(b) CSF infections

Supplementary Data

Supplementary Figure 1

Flow chart of isolates included in the analysis



CSF: Cerebrospinal fluid, NICU: Neonatal Intensive Care Unit or Special Care Nursery

* Contaminants excluded: *Actinomyces naeslundii*, *Actinomyces odontolyticus*, *Aerococcus viridans*, *Bacillus cereus*, *Bacillus* spp., *Bacteroides vulgatus*, Coagulase negative staphylococcus (CoNS; in infants not admitted to PICU or <72h), *Corynebacterium minutissimum*, *Corynebacterium striatum*, *Empedobacter brevis*, *Enterococcus durans*, *Enterococcus hirae*, *Kocuria varians*, *Lactococcus lactis* subspecies *lactis*, *Leuconostoc pseudomesenteroides*, *Micrococcus luteus*, *Micrococcus* spp., *Moraxella osloensis*, *Morganella morganii*, *Neisseria cinerea*, *Paenibacillus* spp., *Paenibacillus urinalis*, *Raoultella ornithinolytica*, *Staphylococcus auricularis*, *Staphylococcus capitis*, *Staphylococcus caprae*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Staphylococcus hominis*, *Staphylococcus lugdunensis*, *Staphylococcus saprophyticus*, *Staphylococcus* spp., *Staphylococcus warneri*, *Staphylococcus xylosus*, *Streptococcus anginosus*, *Streptococcus constellatus* subspecies *pharynges*, *Streptococcus milleri* group, *Streptococcus mitis*/*Streptococcus oralis* group, *Streptococcus parasanguinis*, *Streptococcus peroris*, *Streptococcus salivarius*, *Streptococcus sanguinis*, *Streptococcus vestibularis*, *Viridans* group *Streptococcus*.

^Further likely contaminants removed (CoNS removed as indicated in the flowchart): *Actinomyces naeslundii*, *Bacillus cereus*, *Bacillus* species, *Corynebacterium minutissimum*, *Corynebacterium striatum*, *Empedobacter brevis*, *Enterococcus durans*, *Enterococcus hirae*, *Kocuria varians*, *Lactococcus lactis* subspecies *lactis*, *Leuconostoc pseudomesenteroides*, *Micrococcus luteus*, *Micrococcus* spp., *Paenibacillus* spp., *Paenibacillus urinalis*, *Raoultella ornithinolytica*, *Streptococcus anginosus*, *Streptococcus milleri* group, *Streptococcus mitis*/*Streptococcus oralis* group, *Streptococcus parasanguinis*, *Streptococcus peroris*, *Streptococcus salivarius*, *Streptococcus sanguinis*, *Streptococcus vestibularis*, *Viridans* group *Streptococcus*.

† One duplicate (same day) blood culture result retained for additional antimicrobial susceptibility results only.

**Supplementary Table 1:
Pre-defined bacteria-antibiotic susceptibility profiles evaluated**

Gram-positive organisms
<i>Staphylococcus aureus</i>
flu/dicloxacillin
benzylpenicillin
clindamycin
cotrimoxazole
vancomycin
Streptococcus Group A, B, C and G
benzylpenicillin
ceftriaxone/cefotaxime
clindamycin
erythromycin
<i>Streptococcus pneumoniae</i>
benzylpenicillin: blood culture: S / I or DS / R
benzylpenicillin: CSF culture: S / I or DS / R
clindamycin
co-trimoxazole
ceftriaxone/cefotaxime: Blood culture: S / I or DS / R
ceftriaxone/cefotaxime: CSF culture: S / I or DS / R
vancomycin
Coagulase negative <i>Staphylococcus</i> spp.
flu/dicloxacillin
benzylpenicillin
clindamycin
vancomycin
Other Gram-positive organisms not otherwise specified
benzylpenicillin
aminopenicillin
ceftriaxone/cefotaxime
meropenem
vancomycin
clindamycin
co-trimoxazole
Gram-negative pathogens
<i>Escherichia coli</i>
aminopenicillin
amoxicillin-clavulanate
cephalexin
ceftriaxone
cefotaxime

ceftazidime
cefepime
meropenem
co-trimoxazole
gentamicin
amikacin
tigecycline
fosfomycin
ciprofloxacin
<i>Klebsiella pneumoniae</i>
ceftriaxone
cefotaxime
cefepime
ceftazidime
ciprofloxacin
gentamicin
amikacin
co-trimoxazole
fosfomycin
meropenem
norfloxacin
tigecycline
amoxicillin-clavulanate
<i>Pseudomonas aeruginosa</i>
amikacin
gentamicin
meropenem
fosfomycin
piperacillin-tazobactam
ciprofloxacin
ceftazidime
cefepime
<i>Acinetobacter spp.</i>
gentamicin
amikacin
meropenem
tigecycline
minocycline
cefepime
ciprofloxacin
co-trimoxazole
piperacillin-tazobactam

Other Gram-negative pathogens not otherwise listed
aminopenicillin
ampicillin-clavulanate
cephalexin
ceftriaxone/cefotaxime
ceftazidime
cefepime
meropenem
co-trimoxazole
trimethoprim
gentamicin
amikacin
tigecycline
fosfomycin
ciprofloxacin
piperacillin-tazobactam

Supplementary Table 2:

**Early-onset neonatal sepsis incidence rates across the study period
for the five hospitals included in the study**

Year	Total births in study hospitals	Total EOS cases	EOS incidence per 1,000 livebirths
2010	9152	6	0.66
2011	NA	6	NA
2012	9683	6	0.62
2013	9717	9	0.93
2014	10106	8	0.79
2015	14211	14	0.99
2016	14752	11	0.75
2017	14616	13	0.89
2018	14200	9	0.63
2019	14369	11	0.77

NA: Data not available.

Supplementary Table 3

Gram-positive Blood Culture Isolate Antimicrobial Susceptibility Profiles

Organism	Antibiotic	Overall		Sites^	Year 2010- 2014				Year 2015-2019				p value
		S/T	%S		n	S/T	% S	95 % CI	n	S/T	% S	95 % CI	
<i>Streptococcus agalactiae</i> , n=76	Ceftriaxone/Cefotaxime	11/11	100	All	19	4/4	100	40-100	57	7/7	100	59-100	
				West	19	4/4	100	40-100	0	-	-	-	
	Clindamycin	27/39	69	All	19	2/4	50	7-93	57	25/35	71	54-85	0.573
				West	19	2/4	50	7-93	25	11/15	73	45-92	0.557
	Erythromycin	32/44	73	All	19	14/19	74	49-91	57	18/25	72	51-88	0.901
				West	19	14/19	74	49-91	25	18/25	72	51-88	0.901
Penicillin	76/76	100	All	19	19/19	100	82-100	57	57/57	100	94-100		
			West	19	19/19	100	82-100	25	25/25	100	86-100		
<i>Enterococcus faecalis</i> , n=56	Ampicillin	39/39	100	All	19	19/19	100	82-100	37	20/20	100	83-100	n/a
				West	19	19/19	100	82-100	20	20/20	100	83-100	
	Clindamycin	0/13	0	All	19	0/7	0	0-41	37	0/6	0	0-46	n/a
				West	19	0/7	0	0-41	20	0/6	0	0-46	
	Cotrimoxazole	1/16	6	All	19	0/7	0	0-41	37	1/9	11	0-48	1
				West	19	0/7	0	0-41	20	1/9	11	0-48	1
	Penicillin	34/35	97	All	19	17/18	94	73-100	37	17/17	100	80-100	1
				West	19	17/18	94	73-100	20	17/17	100	80-100	1
Vancomycin	55/55	100	All	19	19/19	100	82-100	37	36/36	100	90-100	n/a	
			West	19	19/19	100	82-100	20	19/19	100	82-100		
<i>Staphylococcus aureus</i> , n=53	Clindamycin	42/46	91	All	22	22/22	100	85-100	31	20/24	83	63-95	0.11
				West	22	22/22	100	85-100	9	7/9	78	40-97	0.077
	Cotrimoxazole	25/27	93	All	22	16/17	94	71-100	31	9/10	90	55-100	1
				West	22	16/17	94	71-100	9	9/9	100	66-100	1
	Flucloxacillin/Dicloxacillin	44/53	83	All	22	17/22	77	55-92	31	27/31	87	70-96	0.463
				West	22	17/22	77	55-92	9	8/9	89	52-100	0.642
Penicillin	5/53	9	All	22	2/22	9	1-29	31	3/31	10	2-26	1	

				West	22	2/22	9	1-29	9	0/9	0	0-34	1
	Vancomycin	40/40	100	All	22	22/22	100	85-100	31	18/18	100	81-100	
				West	22	22/22	100	85-100	9	9/9	100	66-100	
<i>Streptococcus pneumoniae</i> , n=4	Ceftriaxone/Cefotaxime	1/1	100	All	0	-	-	-	4	1/1	100	3-100	
	Clindamycin	1/1	100	All	0	-	-	-	4	1/1	100	3-100	
	Penicillin†	3/4	75	All	0	-	-	-	4	3/4	75	19-99	
	Vancomycin	1/1	100	All	0	-	-	-	4	1/1	100	3-100	
<i>Streptococcus pyogenes</i> , n=3	Ceftriaxone/Cefotaxime	2/2	100	All	0	-	-	-	2	2/2	100	16-100	
				West	0	-	-	-	2	2/2	100	16-100	
	Erythromycin	3/3	100	All	1	1/1	100	3-100	2	2/2	100	16-100	
				West	1	1/1	100	3-100	2	2/2	100	16-100	
	Penicillin	3/3	100	All	1	1/1	100	3-100	2	2/2	100	16-100	
			West	1	1/1	100	3-100	2	2/2	100	16-100		
<i>Actinomyces odontolyticus</i> , n=2	Clindamycin	2/2	100	All	0	-	-	-	2	2/2	100	16-100	
	Cotrimoxazole	1/1	100	All	0	-	-	-	2	1/1	100	3-100	
	Penicillin	2/2	100	All	0	-	-	-	2	2/2	100	16-100	
	Vancomycin	1/1	100	All	0	-	-	-	2	1/1	100	3-100	
<i>Streptococcus cristatus</i> , n=1	Ceftriaxone/Cefotaxime	1/1	100	All	0	-	-	-	1	1/1	100	3-100	
	Penicillin	1/1	100	All	0	-	-	-	1	1/1	100	3-100	
	Vancomycin	1/1	100	All	0	-	-	-	1	1/1	100	3-100	

n: number of blood cultures collected; T: number of isolates tested; S: Susceptible; CI: Confidence interval.

*West;: Data from New South Wales Health Pathology West Hospitals: Nepean, Children's Hospital at Westmead and Wagga Wagga Base Hospitals

† 0/4 *Streptococcus pneumoniae* isolates were resistant to penicillin, 3/4 reported as susceptible and 1/4 "less susceptible"

Supplementary Table 4

Gram-negative Blood Culture Antimicrobial Susceptibility Profiles

Organism	Antibiotic	Overall		Site^	Year 2010- 2014				Year 2015-2019				P value
		S/T	% S		n	S/T	% S	95 % CI	n	S/T	% S	95 % CI	
<i>Escherichia coli</i> , n=113	Amikacin	75/75	100	All	42	40/40	100	91-100	71	35/35	100	90-100	-
				West	42	40/40	100	91-100	34	34/34	100	90-100	-
	Amoxicillin-clavulanate	59/77	77	All	42	32/40	80	64-91	71	27/37	73	56-86	0.47
				West	42	32/40	80	64-91	34	26/34	76	59-89	0.71
	Ampicillin	33/74	45	All	42	18/41	44	28-60	71	15/33	45	28-64	0.89
				West	42	18/41	44	28-60	34	15/33	45	28-64	0.89
	Cefepime	57/65	88	All	42	28/29	97	82-100	71	29/36	81	64-92	0.066
				West	42	28/29	97	82-100	34	29/34	85	69-95	0.205
	Ceftazidime	68/74	92	All	42	39/40	98	87-100	71	29/34	85	69-95	0.088
				West	42	39/40	98	87-100	34	29/34	85	69-95	0.088
	Ceftriaxone/Cefotaxime	100/109	92	All	42	38/40	95	83-99	71	62/69	90	80-96	0.481
				West	42	38/40	95	83-99	34	29/34	85	69-95	0.236
	Ciprofloxacin	73/86	85	All	42	37/41	90	77-97	71	36/45	80	65-90	0.185
				West	42	37/41	90	77-97	34	28/34	82	65-93	0.497
Trimethoprim-sulfamethoxazole	55/73	75	All	42	33/39	85	69-94	71	22/34	65	46-80	0.049	
			West	42	33/39	85	69-94	34	22/32	69	50-84	0.11	
Gentamicin/Tobramycin	101/113	89	All	42	40/42	95	84-99	71	61/71	86	76-93	0.205	
			West	42	40/42	95	84-99	34	27/34	79	62-91	0.069	
Meropenem	78/78	100	All	42	41/41	100	91-100	71	37/37	100	91-100	-	
			West	42	41/41	100	91-100	34	34/34	100	90-100	-	
Tigecycline	4/4	100	All	0	-	-	-	71	4/4	100	40-100	-	
			West	0	-	-	-	34	4/4	100	40-100	-	
<i>Enterobacter cloacae</i> complex, n=23	Amikacin	16/16	100	All	12	12/12	100	74-100	11	4/4	100	40-100	-
				West	12	12/12	100	74-100	3	3/3	100	29-100	-
	Amoxicillin-clavulanate	0/15	0	All	12	0/12	0	0-26	11	0/3	0	0-71	-
				West	12	0/12	0	0-26	3	0/3	0	0-71	-

	Ampicillin	0/15	0	All	12	0/12	0	0-26	11	0/3	0	0-71	-
				West	12	0/12	0	0-26	3	0/3	0	0-71	-
	Cefepime	14/16	88	All	12	8/8	100	63-100	11	6/8	75	35-97	0.467
				West	12	8/8	100	63-100	3	3/3	100	29-100	-
	Ceftazidime	11/15	73	All	12	8/12	67	35-90	11	3/3	100	29-100	0.516
				West	12	8/12	67	35-90	3	3/3	100	29-100	0.516
	Ceftriaxone/Cefotaxime	2/22	9	All	12	2/12	17	2-48	11	0/10	0	0-31	0.480
				West	12	2/12	17	2-48	3	0/3	0	0-71	1
	Ciprofloxacin	19/19	100	All	12	12/12	100	74-100	11	7/7	100	59-100	-
				West	12	12/12	100	74-100	3	3/3	100	29-100	-
	Trimethoprim-sulfamethoxazole	17/17	100	All	12	12/12	100	74-100	11	5/5	100	48-100	-
				West	12	12/12	100	74-100	3	3/3	100	29-100	-
	Gentamicin/Tobramycin	20/23	87	All	12	11/12	92	62-100	11	9/11	82	48-98	0.59
				West	12	11/12	92	62-100	3	3/3	100	29-100	1
Meropenem	19/20	95	All	12	11/11	100	72-100	11	8/9	89	52-100	0.45	
			West	12	11/11	100	72-100	3	3/3	100	29-100	-	
Piperacillin-tazobactam	7/17	41	All	12	5/7	71	29-96	11	2/10	20	3-56	0.058	
			West	12	5/7	71	29-96	3	2/3	67	9-99	1	
Tigecycline	1/1	100	All	0	-	-	-	11	1/1	100	3-100	-	
Trimethoprim	14/14	100	All	12	11/11	100	72-100	11	3/3	100	29-100	-	
			West	12	11/11	100	72-100	3	3/3	100	29-100	-	
<i>Klebsiella pneumoniae</i> , n=19	Amikacin	8/8	100	All	6	6/6	100	54-100	13	2/2	100	16-100	-
				West	6	6/6	100	54-100	2	2/2	100	16-100	-
	Amoxicillin-clavulanate	10/10	100	All	6	6/6	100	54-100	13	4/4	100	40-100	-
				West	6	6/6	100	54-100	2	2/2	100	16-100	-
	Cefepime	10/10	100	All	6	6/6	100	54-100	13	4/4	100	40-100	-
				West	6	6/6	100	54-100	2	2/2	100	16-100	-
	Ceftazidime	8/8	100	All	6	6/6	100	54-100	13	2/2	100	16-100	-
				West	6	6/6	100	54-100	2	2/2	100	16-100	-
	Ceftriaxone/Cefotaxime	19/19	100	All	6	6/6	100	54-100	13	13/13	100	75-100	-
				West	6	6/6	100	54-100	2	2/2	100	16-100	-
	Ciprofloxacin	9/9	100	All	6	6/6	100	54-100	13	3/3	100	29-100	-
				West	6	6/6	100	54-100	2	2/2	100	16-100	-

	Trimethoprim-sulfamethoxazole	8/8	10	All	6	6/6	100	54-100	13	2/2	100	16-100	-	
			0	West	6	6/6	100	54-100	2	2/2	100	16-100	-	
	Gentamicin/Tobramycin	19/19	10	All	6	6/6	100	54-100	13	13/13	100	75-100	-	
			0	West	6	6/6	100	54-100	2	2/2	100	16-100	-	
	Meropenem	8/8	10	All	6	6/6	100	54-100	13	2/2	100	16-100	-	
			0	West	6	6/6	100	54-100	2	2/2	100	16-100	-	
	Norfloxacin	4/4	10	All	6	2/2	100	16-100	13	2/2	100	16-100	-	
			0	West	6	2/2	100	16-100	2	2/2	100	16-100	-	
	<i>Pseudomonas aeruginosa</i> , n=14	Amikacin	5/5	10	All	1	1/1	100	3-100	13	4/4	100	40-100	-
				0	West	1	1/1	100	3-100	4	4/4	100	40-100	-
Cefepime		7/7	10	All	1	1/1	100	3-100	13	6/6	100	54-100	-	
			0	West	1	1/1	100	3-100	4	4/4	100	40-100	-	
Ceftazidime		13/14	93	All	1	0/1	0	0-98	13	13/13	100	75-100	0.071	
				West	1	0/1	0	0-98	4	4/4	100	40-100	0.2	
Ciprofloxacin		7/7	10	All	1	1/1	100	3-100	13	6/6	100	54-100	-	
			0	West	1	1/1	100	3-100	4	4/4	100	40-100	-	
Gentamicin/Tobramycin		14/14	10	All	1	1/1	100	3-100	13	13/13	100	75-100	-	
			0	West	1	1/1	100	3-100	4	4/4	100	40-100	-	
Meropenem	7/7	10	All	1	1/1	100	3-100	13	6/6	100	54-100	-		
		0	West	1	1/1	100	3-100	4	4/4	100	40-100	-		
Piperacillin-tazobactam	14/14	10	All	1	1/1	100	3-100	13	13/13	100	75-100	-		
		0	West	1	1/1	100	3-100	4	4/4	100	40-100	-		
<i>Acinetobacter spp.</i> , n=11	Amikacin	8/8	10	All	4	4/4	100	40-100	7	4/4	100	40-100	-	
			0	West	4	4/4	100	40-100	5	4/4	100	40-100	-	
	Cefepime	6/6	10	All	4	4/4	100	40-100	7	2/2	100	16-100	-	
			0	West	4	4/4	100	40-100	5	2/2	100	16-100	-	
	Ciprofloxacin	10/10	10	All	4	4/4	100	40-100	7	6/6	100	54-100	-	
			0	West	4	4/4	100	40-100	5	5/5	100	48-100	-	
	Trimethoprim-sulfamethoxazole	4/5	80	All	4	2/3	67	9-99	7	2/2	100	16-100	1	
				West	4	2/3	67	9-99	5	2/2	100	16-100	1	
	Gentamicin/Tobramycin	10/11	91	All	4	3/4	75	19-99	7	7/7	100	59-100	0.36	
				West	4	3/4	75	19-99	5	5/5	100	48-100	0.44	

	Meropenem	9/9	10 0	All	4	3/3	100	29-100	7	6/6	100	54-100	-
				West	4	3/3	100	29-100	5	5/5	100	48-100	-
	Piperacillin-tazobactam	10/10	10 0	All	4	3/3	100	29-100	7	7/7	100	59-100	-
				West	4	3/3	100	29-100	5	5/5	100	48-100	-
<i>Serratia marcescens</i> , n=8	Amikacin	3/3	10 0	All	2	2/2	100	16-100	6	1/1	100	3-100	-
				West	2	2/2	100	16-100	1	1/1	100	3-100	-
	Amoxicillin-clavulanate	0/3	0	All	2	0/2	0	0-84	6	0/1	0	0-98	-
				West	2	0/2	0	0-84	1	0/1	0	0-98	-
	Ampicillin	0/3	0	All	2	0/2	0	0-84	6	0/1	0	0-98	-
				West	2	0/2	0	0-84	1	0/1	0	0-98	-
	Cefepime	4/4	10 0	All	2	2/2	100	16-100	6	2/2	100	16-100	-
				West	2	2/2	100	16-100	1	1/1	100	3-100	-
	Ceftazidime	3/3	10 0	All	2	2/2	100	16-100	6	1/1	100	3-100	-
				West	2	2/2	100	16-100	1	1/1	100	3-100	-
	Ceftriaxone/Cefotaxime	1/8	12	All	2	1/2	50	1-99	6	0/6	0	0-46	0.25
				West	2	1/2	50	1-99	1	0/1	0	0-98	1
	Ciprofloxacin	6/6	10 0	All	2	2/2	100	16-100	6	4/4	100	40-100	-
				West	2	2/2	100	16-100	1	1/1	100	3-100	-
	Trimethoprim-sulfamethoxazole	3/3	10 0	All	2	2/2	100	16-100	6	1/1	100	3-100	-
				West	2	2/2	100	16-100	1	1/1	100	3-100	-
	Gentamicin/Tobramycin	8/8	10 0	All	2	2/2	100	16-100	6	6/6	100	54-100	-
				West	2	2/2	100	16-100	1	1/1	100	3-100	-
	Meropenem	4/4	10 0	All	2	2/2	100	16-100	6	2/2	100	16-100	-
				West	2	2/2	100	16-100	1	1/1	100	3-100	-
Piperacillin-tazobactam	5/5	10 0	All	2	2/2	100	16-100	6	3/3	100	29-100	-	
			West	2	2/2	100	16-100	1	1/1	100	3-100	-	
Trimethoprim	3/3	10 0	All	2	2/2	100	16-100	6	1/1	100	3-100	-	
			West	2	2/2	100	16-100	1	1/1	100	3-100	-	
	Amikacin	2/2		All	0	-	-	-	7	2/2	100	16-100	-

<i>Klebsiella aerogenes</i> , n=7			10 0	West	0	-	-	-	2	2/2	100	16-100	-
	Amoxicillin-clavulanate	0/2	0	All	0	-	-	-	7	0/2	0	0-84	-
				West	0	-	-	-	2	0/2	0	0-84	-
	Ampicillin	0/2	0	All	0	-	-	-	7	0/2	0	0-84	-
				West	0	-	-	-	2	0/2	0	0-84	-
	Cefepime	3/3	10 0	All	0	-	-	-	7	3/3	100	29-100	-
				West	0	-	-	-	2	2/2	100	16-100	-
	Ceftazidime	0/2	0	All	0	-	-	-	7	0/2	0	0-84	-
				West	0	-	-	-	2	0/2	0	0-84	-
	Ceftriaxone/Cefotaxime	0/7	0	All	0	-	-	-	7	0/7	0	0-41	-
				West	0	-	-	-	2	0/2	0	0-84	-
	Ciprofloxacin	3/3	10 0	All	0	-	-	-	7	3/3	100	29-100	-
				West	0	-	-	-	2	2/2	100	16-100	-
	Trimethoprim-sulfamethoxazole	2/2	10 0	All	0	-	-	-	7	2/2	100	16-100	-
West				0	-	-	-	2	2/2	100	16-100	-	
Gentamicin/Tobramycin	7/7	10 0	All	0	-	-	-	7	7/7	100	59-100	-	
			West	0	-	-	-	2	2/2	100	16-100	-	
Meropenem	6/6	10 0	All	0	-	-	-	7	6/6	100	54-100	-	
			West	0	-	-	-	2	2/2	100	16-100	-	
Trimethoprim	1/1	10 0	All	0	-	-	-	7	1/1	100	3-100	-	
			West	0	-	-	-	2	1/1	100	3-100	-	
<i>Klebsiella oxytoca</i> , n=4	Cefepime	2/2	10 0	All	0	-	-	-	4	2/2	100	16-100	-
	Ceftriaxone/Cefotaxime	4/4	10 0	All	0	-	-	-	4	4/4	100	40-100	-
	Ciprofloxacin	1/1	10 0	All	0	-	-	-	4	1/1	100	3-100	-
	Gentamicin/Tobramycin	4/4	10 0	All	0	-	-	-	4	4/4	100	40-100	-
	Piperacillin-tazobactam	3/3	10 0	All	0	-	-	-	4	3/3	100	29-100	-
	Amikacin	1/1		All	0	-	-	-	2	1/1	100	3-100	-

<i>Citrobacter freundii</i> , n=2			10 0	West	0	-	-	-	1	1/1	100	3-100	-
	Amoxicillin-clavulanate	0/1	0	All	0	-	-	-	2	0/1	0	0-98	-
				West	0	-	-	-	1	0/1	0	0-98	-
	Ampicillin	0/1	0	All	0	-	-	-	2	0/1	0	0-98	-
				West	0	-	-	-	1	0/1	0	0-98	-
	Cefepime	2/2	10 0	All	0	-	-	-	2	2/2	100	16-100	-
				West	0	-	-	-	1	1/1	100	3-100	-
	Ceftazidime	1/1	10 0	All	0	-	-	-	2	1/1	100	3-100	-
				West	0	-	-	-	1	1/1	100	3-100	-
	Ceftriaxone/Cefotaxime	0/2	0	All	0	-	-	-	2	0/2	0	0-84	-
				West	0	-	-	-	1	0/1	0	0-98	-
	Ciprofloxacin	2/2	10 0	All	0	-	-	-	2	2/2	100	16-100	-
				West	0	-	-	-	1	1/1	100	3-100	-
	Trimethoprim-sulfamethoxazole	2/2	10 0	All	0	-	-	-	2	2/2	100	16-100	-
				West	0	-	-	-	1	1/1	100	3-100	-
	Gentamicin/Tobramycin	2/2	10 0	All	0	-	-	-	2	2/2	100	16-100	-
West				0	-	-	-	1	1/1	100	3-100	-	
Meropenem	2/2	10 0	All	0	-	-	-	2	2/2	100	16-100	-	
			West	0	-	-	-	1	1/1	100	3-100	-	
Piperacillin-tazobactam	1/2	50	All	0	-	-	-	2	1/2	50	1-99	-	
			West	0	-	-	-	1	1/1	100	3-100	-	
Trimethoprim	1/1	10 0	All	0	-	-	-	2	1/1	100	3-100	-	
			West	0	-	-	-	1	1/1	100	3-100	-	
<i>Pseudomonas oryzihabitans</i> , n=2	Amikacin	2/2	10 0	All	1	1/1	100	3-100	1	1/1	100	3-100	-
				West	1	1/1	100	3-100	1	1/1	100	3-100	-
	Ampicillin	0/1	0	All	1	0/1	0	0-98	0	-	-	-	-
				West	1	0/1	0	0-98	0	-	-	-	-
	Ceftazidime	1/1	10 0	All	0	-	-	-	1	1/1	100	3-100	-
West				0	-	-	-	1	1/1	100	3-100	-	

	Ceftriaxone/Cefotaxime	1/1	10 0	All	0	-	-	-	1	1/1	100	3-100	-
				West	0	-	-	-	1	1/1	100	3-100	-
	Ciprofloxacin	2/2	10 0	All	1	1/1	100	3-100	1	1/1	100	3-100	-
				West	1	1/1	100	3-100	1	1/1	100	3-100	-
	Gentamicin/Tobramycin	2/2	10 0	All	1	1/1	100	3-100	1	1/1	100	3-100	-
				West	1	1/1	100	3-100	1	1/1	100	3-100	-
	Meropenem	2/2	10 0	All	1	1/1	100	3-100	1	1/1	100	3-100	-
				West	1	1/1	100	3-100	1	1/1	100	3-100	-
	Piperacillin-tazobactam	1/1	10 0	All	0	-	-	-	1	1/1	100	3-100	-
				West	0	-	-	-	1	1/1	100	3-100	-
<i>Burkholderia cepacia</i> , n=1	Ciprofloxacin	1/1	10 0	All	0	-	-	-	1	1/1	100	3-100	-
	Gentamicin/Tobramycin	1/1	10 0	All	0	-	-	-	1	1/1	100	3-100	-
<i>Haemophilus influenzae</i> , n=1	Ceftriaxone/Cefotaxime	1/1	10 0	All	0	-	-	-	1	1/1	100	3-100	-
<i>Haemophilus parainfluenzae</i> , n=1	Ceftriaxone/Cefotaxime	1/1	10 0	All	0	-	-	-	1	1/1	100	3-100	-
<i>Leclercia adecarboxylata</i> , n=1	Ceftriaxone/Cefotaxime	1/1	10 0	All	0	-	-	-	1	1/1	100	3-100	-
	Ciprofloxacin	1/1	10 0	All	0	-	-	-	1	1/1	100	3-100	-
	Gentamicin/Tobramycin	1/1	10 0	All	0	-	-	-	1	1/1	100	3-100	-
<i>Morganella morganii</i> , n=1	Amikacin	1/1	10 0	All	0	-	-	-	1	1/1	100	3-100	-
				West	0	-	-	-	1	1/1	100	3-100	-
	Amoxicillin-clavulanate	0/1	0	All	0	-	-	-	1	0/1	0	0-98	-
				West	0	-	-	-	1	0/1	0	0-98	-
	Ampicillin	0/1	0	All	0	-	-	-	1	0/1	0	0-98	-
				West	0	-	-	-	1	0/1	0	0-98	-
Cefepime	1/1	10 0	All	0	-	-	-	1	1/1	100	3-100	-	
			West	0	-	-	-	1	1/1	100	3-100	-	
Ceftazidime	1/1		All	0	-	-	-	1	1/1	100	3-100	-	

			10 0	West	0	-	-	-	1	1/1	100	3-100	-
	Ceftriaxone/Cefotaxime	0/1	0	All	0	-	-	-	1	0/1	0	0-98	-
				West	0	-	-	-	1	0/1	0	0-98	-
	Ciprofloxacin	1/1	10 0	All	0	-	-	-	1	1/1	100	3-100	-
				West	0	-	-	-	1	1/1	100	3-100	-
	Trimethoprim-sulfamethoxazole	1/1	10 0	All	0	-	-	-	1	1/1	100	3-100	-
				West	0	-	-	-	1	1/1	100	3-100	-
	Gentamicin/Tobramycin	1/1	10 0	All	0	-	-	-	1	1/1	100	3-100	-
				West	0	-	-	-	1	1/1	100	3-100	-
	Meropenem	1/1	10 0	All	0	-	-	-	1	1/1	100	3-100	-
				West	0	-	-	-	1	1/1	100	3-100	-
	Piperacillin-tazobactam	1/1	10 0	All	0	-	-	-	1	1/1	100	3-100	-
				West	0	-	-	-	1	1/1	100	3-100	-
	Trimethoprim	1/1	10 0	All	0	-	-	-	1	1/1	100	3-100	-
				West	0	-	-	-	1	1/1	100	3-100	-
<i>Proteus mirabilis</i> , n=1	Amikacin	1/1	10 0	All	1	1/1	100	3-100	0	-	-	-	-
				West	1	1/1	100	3-100	0	-	-	-	-
	Amoxicillin-clavulanate	1/1	10 0	All	1	1/1	100	3-100	0	-	-	-	-
				West	1	1/1	100	3-100	0	-	-	-	-
	Ampicillin	1/1	10 0	All	1	1/1	100	3-100	0	-	-	-	-
				West	1	1/1	100	3-100	0	-	-	-	-
	Cefepime	1/1	10 0	All	1	1/1	100	3-100	0	-	-	-	-
				West	1	1/1	100	3-100	0	-	-	-	-
	Ceftazidime	1/1	10 0	All	1	1/1	100	3-100	0	-	-	-	-
				West	1	1/1	100	3-100	0	-	-	-	-
	Ceftriaxone/Cefotaxime	1/1	10 0	All	1	1/1	100	3-100	0	-	-	-	-
				West	1	1/1	100	3-100	0	-	-	-	-
	Ciprofloxacin	1/1	10 0	All	1	1/1	100	3-100	0	-	-	-	-
				West	1	1/1	100	3-100	0	-	-	-	-

	Trimethoprim-sulfamethoxazole	1/1	10 0	All	1	1/1	100	3-100	0	-	-	-	-
				West	1	1/1	100	3-100	0	-	-	-	-
	Gentamicin/Tobramycin	1/1	10 0	All	1	1/1	100	3-100	0	-	-	-	-
				West	1	1/1	100	3-100	0	-	-	-	-
	Meropenem	1/1	10 0	All	1	1/1	100	3-100	0	-	-	-	-
				West	1	1/1	100	3-100	0	-	-	-	-
	Piperacillin-tazobactam	1/1	10 0	All	1	1/1	100	3-100	0	-	-	-	-
				West	1	1/1	100	3-100	0	-	-	-	-
	Tigecycline	0/1	0	All	1	0/1	0	0-98	0	-	-	-	-
				West	1	0/1	0	0-98	0	-	-	-	-
	Trimethoprim	1/1	10 0	All	1	1/1	100	3-100	0	-	-	-	-
				West	1	1/1	100	3-100	0	-	-	-	-

S: Susceptible; T: number of isolates tested; West: New South Wales Health Pathology West hospitals; n: number of blood isolates; CI: Confidence interval

^ Data available for New South Wales Health Pathology West hospitals (Nepean hospital, Children's Hospital at Westmead, and Wagga Wagga Base Hospital) only

Supplementary Table 5.

Gram-negative Cerebrospinal Fluid Culture Antimicrobial Susceptibility Profiles

Pathogen	Antibiotic (number susceptible/number tested; % susceptible)										
	Ampicillin	AMX-CLAV	Ceftriaxone	Cefepime	Ceftazidime	TMP-SMX	Ciprofloxacin	Gentamicin	Amikacin	PIP-TAZ	Meropenem
<i>Escherichia coli</i> , n=7	1/2 (50)	2/2 (100)	6/6 (100)	2/2 (100)	2/2 (100)	2/3 (67)	4/4 (100)	6/6(100)	2/2 (100)		3/3 (100)
<i>Enterobacter cloacae</i> complex n=2			0/2 (0)	2/2 (100)				2/2 (100)		0/1 (0)	
<i>Pseudomonas aeruginosa</i> , n=2					2/2 (100)		1/1 (100)	2/2 (100)		1/1 (100)	1/1 (100)
<i>Pseudomonas luteola</i> , n=1					1/1 (100)		1/1 (100)	1/1 (100)			
<i>Klebsiella oxytoca</i> , n=1			1/1 (100)				1/1 (100)	1/1 (100)			
<i>Neisseria meningitidis</i> , n=1			1/1 (100)								
<i>Serratia liquefaciens</i> , n=1			1/1 (100)				1/1 (100)	1/1 (100)			
<i>Serratia marcescens</i> , n=1			0/1 (0)				1/1 (100)	1/1 (100)			

AMX-CLAV: Amoxicillin-clavulanate; Ceftriaxone: Ceftriaxone or Cefotaxime; TMP-SMX: Trimethoprim-sulfamethoxazole; Gentamicin: Gentamicin or Tobramycin; PIP-TAZ: Piperacillin-tazobactam

Supplementary Table 6

Gram-positive CSF isolate antimicrobial susceptibility profiles

Pathogen	Antibiotic						
	number susceptible/number tested (% susceptible)						
	Penicillin	Erythromycin	Ceftriaxone	Flucloxacillin	Clindamycin	TMP-SMX	Vancomycin
<i>Streptococcus agalactiae</i> , n=11	11/11 (100)	0/4 (0)	5/5 (100)		1/2 (50)		
<i>Staphylococcus aureus</i> , n=5	2/5 (40)			4/5 (80)	4/4 (100)	1/2 (50)	2/2 (100)
<i>Enterococcus faecalis</i> , n=1							1/1 (100)

Ceftriaxone: Ceftriaxone or Cefotaxime, Flucloxacillin: Flucloxacillin or Dicloxacillin; TMP-SMX: Trimethoprim-sulfamethoxazole